

*Randomized trial of combined  
chemotherapy and radiotherapy for  
high risk endometrial carcinoma*

---

---


*PORTEC – 3 / EN7*



*An International Intergroup Trial*

# PORTEC-3

---



- *uniform schedule*
- *upfront pathology review*
- *QoL analysis*




# Eligibility

---

- *Endometrial carcinoma FIGO 2009:*
  - » *stage IA with invasion, grade 3, LVSI+*
  - » *stage IB grade 3*
  - » *stage II*
  - » *stage IIIA or IIIC, IIIB<sub>parametrium</sub>*
  - » *stage IA<sub>invasion</sub>, IB, II or III and serous or clear cell*
- *WHO PS 0-2*
- *no residual macroscopic tumor after surgery*
- *Pathology review before randomisation*



# Accrual – 27 May 2013



# Accrual by group

Group	Arm 1	Arm 2	Total	Past year
Netherlands	64	67	<b>131</b>	18
Italy	42	48	<b>90</b>	16
Australia/NZ	52	56	<b>108</b>	24
Canada	26	32	<b>58</b>	11
UK	88	74	<b>162</b>	56
France	31	27	<b>58</b>	6
<b>Total</b>	<b>303</b>	<b>304</b>	<b>607</b>	<b>131</b>



# PORTEC-3 international collaboration



**Thank you**

**PORTEC - 3**  
International Intergroup Trial

